Enliven Therapeutics (ELVN) Other Non-Current Liabilities (2022 - 2025)

Enliven Therapeutics (ELVN) reported Other Non-Current Liabilities of $103000.0 for Q3 2025, down 49.51% sequentially from $204000.0 in Q2 2025.

Enliven Therapeutics (ELVN) Other Non-Current Liabilities (2022 - 2025) Analysis & Trends

Enliven Therapeutics (ELVN) has 4 years of Other Non-Current Liabilities data on file, last reported at $103000.0 in Q3 2025.

For the quarter ending Q3 2025, Other Non-Current Liabilities changed N/A year-over-year to $103000.0; the trailing twelve-month figure through Sep 2025 stood at $103000.0 (changed N/A YoY), and the FY2023 full-year result was $67000.0, down 89.83% from the prior year.
Other Non-Current Liabilities slipped to $103000.0 in Q3 2025, from $204000.0 in the prior quarter.
In the past five years, Other Non-Current Liabilities ranged from a high of $659000.0 in Q4 2022 to a low of $6000.0 in Q2 2024.
A 4-year average of $245700.0 and a median of $209000.0 in 2023 frame the typical range for Other Non-Current Liabilities.
Across the five-year window, Other Non-Current Liabilities slumped 98.33% in 2024 and soared 3300.0% in 2025, its largest moves.
Tracing ELVN's Other Non-Current Liabilities over 4 years: stood at $659000.0 in 2022, then plunged by 89.83% to $67000.0 in 2023, then sank by 91.04% to $6000.0 in 2024, then soared by 1616.67% to $103000.0 in 2025.
Business Quant data shows ELVN's Other Non-Current Liabilities at $103000.0 in Q3 2025, $204000.0 in Q2 2025, and $302000.0 in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Enliven Therapeutics	3.22 Bn	3.22 Bn	-

Download Data